Iprasol Respirator Solution (2.5 mg + 500 mcg)/3 ml is a combination bronchodilator formulated for inhalation via nebulizer. It contains Salbutamol, a short-acting beta₂-agonist, and Ipratropium Bromide, an anticholinergic bronchodilator. This dual-action combination provides rapid and sustained relief from bronchospasm by targeting two different pathways involved in airway constriction. Iprasol Respirator Solution is widely used in the management of chronic obstructive pulmonary disease (COPD) and bronchial asthma, particularly in patients requiring nebulized therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Combined Bronchodilators
Beta₂-Agonist and Anticholinergic Agents

Composition

Each 3 ml unit dose contains:

• Salbutamol 2.5 mg

• Ipratropium Bromide 500 mcg

Indications

Iprasol Respirator Solution is indicated for:

• Management of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema

• Adjunctive treatment of bronchial asthma

• Acute and chronic obstructive airway conditions where combination bronchodilator therapy is required

It is particularly beneficial for patients who have an inadequate response to single bronchodilator therapy.

Pharmacology

Salbutamol is a selective beta₂-adrenergic agonist that relaxes bronchial smooth muscle by stimulating beta₂ receptors, leading to rapid bronchodilation and improved airflow. Ipratropium Bromide acts by blocking muscarinic receptors in the airways, inhibiting acetylcholine-mediated bronchoconstriction. The combination of these two agents results in enhanced bronchodilation, improved lung function, and prolonged symptom relief. Both drugs act primarily within the lungs, minimizing systemic absorption and reducing the risk of systemic adverse effects.

Dosage and Administration

The dosage of Iprasol Respirator Solution should be determined by a healthcare professional based on the patient’s condition and response to therapy.

• Administered by inhalation using a suitable nebulizer

• The contents of one 3 ml unit are usually used per nebulization session

• May be used alone or diluted with normal saline if required

Patients should be instructed on proper nebulization technique to ensure optimal delivery of medication.

Contraindications

Iprasol Respirator Solution is contraindicated in patients with:

• Known hypersensitivity to salbutamol, ipratropium bromide, atropine, or any component of the formulation

• History of allergic reactions to similar bronchodilator agents

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use with caution in patients with cardiovascular disorders, hypertension, diabetes mellitus, or thyroid disease

• Caution is advised in patients with narrow-angle glaucoma or prostatic hyperplasia

• Avoid contact of nebulized mist with the eyes

• Not intended as the sole therapy for severe acute asthma unless directed by a physician

Adverse Effects

Iprasol Respirator Solution is generally well tolerated. Possible adverse effects include:

• Tremor

• Dry mouth

• Headache

• Palpitations

• Cough or throat irritation

Most adverse effects are mild and transient.

Drug Interactions

Caution is advised when used concomitantly with:

• Other beta-agonists or anticholinergic agents

• Beta-blockers

• Certain diuretics and corticosteroids, which may increase the risk of hypokalemia

Storage

Store in a cool and dry place, protected from light. Do not freeze. Keep out of reach of children.

Conclusion

Iprasol Respirator Solution (2.5 mg + 500 mcg)/3 ml offers effective dual bronchodilation through the combined action of salbutamol and ipratropium bromide. Its nebulized formulation ensures efficient delivery to the lungs, making it an important therapeutic option for patients with COPD and asthma who require enhanced bronchodilator support.